Journals / Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi / 2016 / Cilt: 30 - Sayı: 2

Follow-Up of a Home Care Patient: Warfarin Usage

Evde bakım hastasının izlemi: Varfarin kullanımı

Pages
89–94
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Family physicians' informing caregivers during follow-up of home-care patients, about patients' drugs, drug-drug interactions, especially drug-food interactions regularly is important.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Warfarin is commonly used drug; however its dosage is affected by plenty of food and drugs.
📊
Key Findings & Data:Patients are monitored by International Normalized Ratio (INR), standard value of the prothrombin time, and the target values vary 2-3.5 for different diagnosis.A 76-year-old female patient had a cerebrovascular accident after a cholecystectomy operation.
💡
Conclusion & Impact:Family physicians' informing caregivers during follow-up of home-care patients, about patients' drugs, drug-drug interactions, especially drug-food interactions regularly is important.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:evde bakım · varfarin · INR

Abstract

Warfarin is commonly used drug; however its dosage is affected by plenty of food and drugs. As it can cause bleeding, its follow-up is important. Patients are monitored by International Normalized Ratio (INR), standard value of the prothrombin time, and the target values vary 2-3.5 for different diagnosis.A 76-year-old female patient had a cerebrovascular accident after a cholecystectomy operation. As a sequel she had loss of strength in her right foot. Her caregivers, 77-year-old husband and a professional caregiver, applied to home care services (HCSs). Ecchymosis was seen in her body in her physical examination while vital signs were normal. Additionally decubitus ulcers on her gluteal region, loss of strength at her right foot was determined. She had been in this condition for 5-6 months and the ecchymosis was attributed to impacts during caring. She was referred to emergency department because of bleeding risk. In her first evaluation INR: 6.6, however no bleeding was not detected except for widespread ecchymosis. Warfarin was stopped for 3 days and the treatment regimen was planned again. After 12 days, control INR: 2.96. Family physicians' informing caregivers during follow-up of home-care patients, about patients' drugs, drug-drug interactions, especially drug-food interactions regularly is important.

Özet

Varfarin sık kullanılan ancak kullanım dozu pek çok ilaç ve yiyeceklerde etkilenen bir ilaçtır. Kanamaya neden olabileceğinden izlemi önemlidir. Hastalar Protrombin Zamanı standart değeri olan INR (International Normalized Ratio) ile izlenmekte ve farklı tanılarda hedef değerler 2-3,5 arasında değişmektedir. 76 yaşındaki kadın hasta kolesistektomi operasyonu sonrası serebrovasküler olay geçirmiştir. Hastanın sekel olarak sağ ayağında kuvvet kaybı mevcuttur. Hastaya bakan 77 yaşındaki eşi ve profesyonel bakıcısı evde sağlık hizmetleri (ESH) birimine başvurmuştur. Vital bulguları normal olan hastanın vücudunda ekimozlar görüldü. Ayrıca gluteal bölgesinde bası yaraları, sağ ayakta kuvvet kaybı belirlendi. Hasta 5-6 aydır bu durumda ve morlukları bakım sırasındaki çarpmalara bağlanmış. Kanama riski nedeniyle acil servise sevk edildi. İlk değerlendirmesinde INR: 6,6 olup yaygın ekimoz dışında kanama tespit edilmedi. Varfarin üç gün kesildi ve tedavi rejimi yeniden düzenlendi. Oniki gün sonra bakılan kontrol INR: 2,96’ydi. Aile hekimlerinin evde bakım hastalarının izlemlerinde bakımverenleri hastaların ilaçları, ilaç-ilaç etkileşimleri, özellikle ilaç-gıda etkileşimi konularında düzenli bilgilendirmesi önemlidir.

🔖

Cite This Article

ÇOLAK, M., GÖKDEMİR, Ö., BULUT, Ü., KARTAL, M. (2016). Follow-Up of a Home Care Patient: Warfarin Usage. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, Cilt: 30 - Sayı: 2, 89–94. https://ajindex.com/articles/160668

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Referans1 Türk Hematoloji Derneği, Kumadin Kullanım Rehberi 2010. http://www.thd.org.tr/thd_halk/?sayfa=kkr (Erişim Tarihi 26 Ağustos 2014). Referans2 Hull RD, Therapeutic use of warfarin and other vitamin K antagonists, http://www.uptodate.com/contents/therapeutic-use-of- warfarin-and-other-vitamin-k- antagonists?source=search_result&search=warfarin&sele cted (Erişim Tarihi 29 Haziran 2015). Referans3 Eroğlu SE, A.Denizbaşı A, Özpolat Ç, et al. The Investigation of the Relation Between INR Levels and Risk of Complication in Patients with a History oföWarfarin use, Marmara Medical Journal, 2012; 25; 3, 138-142. Referans4 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167:1414-1419. Referans5 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S- 198S. Referans6 Batke-Hastings S, Carman TL. Sublingual administration of warfarin: a novel form of delivery. Vasc Med 2008; 13:123-126. Referans7 Zhao HJ, Zheng ZT, Wang ZH, et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139:260-270. Referans8 Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8:1216-1222. Referans9 Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100:26-31. Referans10 Anand S, Yusuf S, Xie C, et al. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357:217-227. Referans11 Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713-719. Referans12 Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation